Ventas (VTR)CEO sold ~$802K

~$802K

Approx. value · 10K sh @ $77.66

1.11M

Holds after · shares reported

Traded

Feb 2, 2026

Filed

Feb 3, 2026

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Nov 12, 2025CongressDisclosed purchase of VTR — reported range $1,001 - $15,000
2. Jan 2, 2026Insider · 2 peopleInsiders: 2 sales (~$3.1M)
3. Jan 7, 2026Company filing · Form 8-K · Material agreement, New debtSigned an important agreement, and took on new debt or obligations
4. Jan 9, 2026CongressDisclosed partial sale of VTR — reported range $1,001 - $15,000
5. Jan 21, 20265% stakeJPMORGAN CHASE & CO. reported a passive stake (13G) of 5.9%
6. Feb 2, 2026 · this disclosureInsiderCEO sold ~$802K of VTR shares in the open market

What came next

1. Feb 5, 2026Company filing · Form 8-K · ResultsReported its results
2. Feb 6, 2026InsiderCEO sold ~$849K of VTR shares in the open market
3. Feb 11, 2026Insider · 5 days before an 8-KOfficer sold ~$3.02M of VTR shares in the open market
4. Feb 16, 2026Company filing · Form 8-K · Executive changeChanged a top executive or board member“On February 16, 2026, Gregory R. Liebbe, Senior Vice President, Chief Accounting Officer and Controller informed Ventas, Inc. (the “Company”) that he is resigning to pursue other opportunities.”
5. Mar 27, 20265% stakeThe Vanguard Group reported a passive stake (13G)
6. Apr 27, 2026Company filing · Form 8-K · ResultsReported its results
7. Apr 29, 20265% stakeVanguard Portfolio Management reported a passive stake (13G) of 8.7%
8. Apr 30, 20265% stakeVanguard Capital Management reported a passive stake (13G) of 7.5%
9. May 4, 20265% stakeJPMORGAN CHASE & CO. reported a passive stake (13G) of 7.1%
10. May 12, 2026Company filing · Form 8-K · Executive change, Shareholder voteChanged a top executive or board member, and held a shareholder vote (and 1 more item)“On May 12, 2026, in connection with his previously disclosed retirement on May 1, 2026, Ventas, Inc. (the “Company”) entered into a separation and release agreement with Peter J. Bulgarelli, Executive Vice President, Outpatient Medical & Research, Ventas, Inc. and President and CEO, Lillibridge Healthcare Services, Inc. (the “Separation Agreement”), pursuant to which Mr. Bulgarelli will receive a payment equal to…”
11. May 12, 20265% stakeJPMORGAN CHASE & CO reported a passive stake (13G) of 7.1%
12. May 14, 2026InsiderDirector sold ~$104K of VTR shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Ventas

For Ventas, OQRO holds 1 Congress trade report and 16 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VTR page.

Other recent filings by Debra A Cafaro, Chairman and CEO

• SEC Form 4 at Ventas (VTR)Feb 10, 2026
• SEC Form 4 at Ventas (VTR)Jan 6, 2026
• SEC Form 4 at Ventas (VTR)Dec 3, 2025
• SEC Form 4 at Ventas (VTR)Nov 19, 2025
• SEC Form 4 at Ventas (VTR)Nov 6, 2025

The full history of Debra A Cafaro, Chairman and CEO is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Ventas

• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026

Everything OQRO holds on this company is on its VTR page.